Close Menu

Synthetic Biology

The firm is also pursuing advances in its manufacturing and ordering processes that it says will help it scale to $500 million in annual revenues.

Total fiscal fourth quarter revenues more than doubled while the synthetic DNA maker's fiscal 2020 revenues grew 66 percent to $90.1 million.

In its first complete quarter as a publicly traded company, Berkeley Lights reported $18.2 million in total revenues, including $4.1 million in service revenues.

The company, based in Heidelberg, Germany, attributed the revenue decline to a reduction in US sales following the closure of its San Diego site.

The synbio company offers scale and lower costs in "massive" end markets, SVB Leerink analysts said, and could soon command an even more attractive valuation.

Bloomberg reports AstraZeneca may conduct another study of its candidate SARS-CoV-2 vaccine after dosing error.

Moderna is applying for an Emergency Use Authorization for its coronavirus vaccine, according to the New York Times.

The National Health Service is to conduct a trial of Grail's blood-based screening test for cancer.

In PLOS this week: somatic mutation patterns of glioblastomas among Lebanese patients, phenome-wide study using UK Biobank data, and more.

Dec
10
Sponsored by
Tecan

CRISPR has developed into a core tool to facilitate genome editing, inspiring transformative ideas in engineering biology.